Patient’s own immune cells effective as living medicine for melanoma

A patient’s own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The TIL trial is the world’s first comparative phase 3 trial looking into the effect of T cell therapy in melanoma, and solid tumors in general.

Source: ScienceDaily.com